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Distinct expression and ligand-binding proﬁles of
two constitutively active GPR17 splice variantsbph_633 1092..1105
T Benned-Jensen and MM Rosenkilde
Laboratory for Molecular Pharmacology, Department of Neuroscience and Pharmacology, Faculty of Health Sciences,
The Panum Institute, Copenhagen University, Copenhagen, Denmark
Background and purpose: In humans and non-human primates, the 7TM receptor GPR17 exists in two isoforms differing only
by the length of the N-terminus. Of these, only the short isoform has previously been characterized. Hence, we investigated
gene expression and ligand-binding proﬁles of both splice variants and furthermore uncovered and characterized constitutive
activity of both isoforms.
Experimental approach: Expression levels of the hGPR17 isoforms were determined in several brain regions as well as heart
and kidney using quantitative RT-PCR. A CREB reporter assay and [35S]-GTPgS binding were employed to assess the constitutive
activity and the activation by UDP, UDP-glucose and -galactose and the cysteinyl leukotrienes LTC4 and LTD4. Leukotriene
binding and induction of internalization were furthermore tested using homologous competition binding and antibody-
feeding experiments respectively.
Key results: The short isoform (hGPR17-S) was expressed more abundantly (eight- to 23-fold) in the brain than the long
isoform (hGPR17-L), whereas the opposite was observed in heart and kidney. As previously reported, the uracil nucleotides
activated hGPR17-S with micromolar potencies. However, much lower potencies were observed for hGPR17-L with a 50- to
170-fold increase in EC50. Furthermore, contrary to previous reports, neither of the isoforms was activated or bound by the
cysteinyl leukotrienes. Finally, both receptors were demonstrated to be constitutively active through Gai.
Conclusions and implications: We present the ﬁrst isoform-speciﬁc characterization of GPR17 and show that differences exist
between the isoforms, in both expression pattern and pharmacological proﬁle. In turn, our results indicate that the two human
isoforms might serve tissue-speciﬁc functions.
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Introduction
The group of rhodopsin-like seven transmembrane-spanning
(7TM) receptors constitutes one of the largest superfamilies of
proteins in humans and vertebrates in general. These recep-
tors, also known as G protein-coupled receptors, are targets
for an extraordinarily large repertoire of endogenous ligands,
which shows a vast variation in structure, size and chemical
properties. The diverse group of ligands illustrates the
involvement of 7TM receptors in a great variety of physiologi-
cal processes, which ranges from regulation of blood pressure,
over modulation of leukocyte trafﬁcking and appetite control
to visualization (Schwartz and Holst, 2003). The existence of
splice variants further diversiﬁes 7TM receptor signal trans-
duction and expression patterns. Thus, several 7TM receptor
splice variants have been shown to differ by their pharmaco-
logical proﬁles, constitutive activity, internalization pattern
or tissue distribution (Kilpatrick et al., 1999). Importantly, a
study using dopamine D2 receptor knockout mice demon-
strated that two splice variants of this receptor indeed play
speciﬁc roles in vivo effectively demonstrating the relevance of
receptor splice variants (Usiello et al., 2000).
The 7TM receptor GPR17 was cloned in the search of new
chemokine receptors, using human genomic DNA as template
(Raport et al., 1996). The same ﬁnding was later obtained by
another group (Blasius et al., 1998). However, having used
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encoding a receptor with a 28 amino acid longer N-terminus
(Blasius et al., 1998). Today it is known that in humans and
other primates, but not in lower species, alternative splicing
results in two GPR17 isoforms that differ solely with regard to
the length of the N-terminus. Of these, only the short isoform
has been a subject of study so far (Ciana et al., 2006; Lecca
et al., 2008; Parravicini et al., 2008; Ceruti et al., 2009;
Maekawa et al., 2009; Temporini et al., 2009). Phylogeneti-
cally, GPR17 is most closely related to members of the P2Y
nucleotide receptor subfamily containing, among others, the
P2Y-speciﬁc sequence ‘ﬁngerprint’ in transmembrane (TM) 3
(FLFYxNLYxSILFLTCISx). Besides the P2Y receptors, GPR17 is
also structurally related to the two cysteinyl receptors CysLT1
and CysLT2 and is the closest human homologue to the
Epstein–Barr virus-induced receptor 2 (EBI2).
Given the structural resemblance to both P2Y and cysteinyl
leukotriene receptors, the short human GPR17 isoform as well
as the rat and murine GPR17 were recently suggested to be
targeted by two distinct types of agonists, namely cysteinyl
leukotrienes and uracil nucleotides (Ciana et al., 2006; Lecca
et al., 2008). According to these studies, LTC4 and LTD4 acti-
vated the receptors with EC50 values in the nM range, while
UDP, UDP-glucose and UDP-galactose activated them with
EC50 values in the mM range (Ciana et al., 2006). It was fur-
thermore shown that GPR17 expression was up-regulated in a
rat model of ischaemic damage and that knock-down of the
receptor prevented ischaemia, suggesting that GPR17 puta-
tively could function as a mediator of brain damage (Ciana
et al., 2006). The same phenomenon was later observed in the
equivalent murine model of ischaemia (Lecca et al., 2008) and
in a model of spinal cord injury (Ceruti et al., 2009). Very
recently, GPR17 was shown to function as a negative regulator
of CysLT1 receptor activation in stable cell lines by inhibiting
LTD4 binding to CysLT1. This regulatory effect was further-
more conﬁrmed both in bone marrow-derived macrophages
by shRNA-mediated knock-down and in GPR17-deﬁcient
mice. Of note, no binding of LTC4 and LTD4 to GPR17 was
seen in this study (Maekawa et al., 2009)
In the present study, we carry out a detailed expression
analysis of the two human GPR17 isoforms in a range of brain
regions as well as the heart and kidney. Using several different
assays, we furthermore demonstrate that both of these iso-
forms and the murine GPR17 are constitutively active via Gai.
In addition, we uncovered a difference in the pharmacologi-
cal proﬁles of the two human isoforms by showing that the
short isoform is activated more potently by uracil nucleotides
than the long isoform. Finally, by employing [
35S]-GTPgS
binding and competition binding, in line with the very recent
report by Maekawa et al. (2009), we demonstrated that
neither of the human isoforms nor the mGPR17 are activated
by or bound by the leukotrienes LTD4 and LTC4.
Methods
Materials
Receptor nomenclature throughout the manuscript conforms
to the British Journal of Pharmacology Guide to Receptors
and Channels (Alexander et al., 2008). The long isoform
of hGPR17, hGPR17-L (GenBank accession number
NM_005291) was kindly provided by H.R. Luttichau, Labora-
tory for Molecular Pharmacology. The promiscuous chimeric
G protein GaD6qi4myr (abbreviated Gqi4myr) was kindly
provided by Evi Kostenis (Rheinische Friedrich-Wilhelm Uni-
versity, Bonn, Germany). Lipofectamine
TM 2000 reagent and
OPTIMEM were purchased from Life Technologies. SteadyLite
(Lyophilized Substrate Solution) was from Packard (Boston,
MA, USA). Goat anti-mouse horseradish peroxidase-
conjugated antibody was from Pierce (Rockford, IL, USA),
while mouse anti-M1-FLAG antibody, Ticlopidine (P2Y12
receptor antagonist), forskolin and pertussis toxin were from
Sigma Chemicals Co. (St. Louis, MO, USA). Montelukast
(CysLT1 receptor antagonist) was from Sequoia Research
Products (Oxford, UK). Both the SlowFade Antifade reagent
and goat anti-mouse Alexa Fluor 488-conjugated and
Alexa Flour 568-conjugated antibodies were from Molecular
Probes (Carlsbad, CA, USA). The TMB (3,3’,5,5’-
tetramethylbenzidine) substrate was purchased from KemEn-
Tech (Taastrup, Denmark).
DMEM was purchased from Invitrogen; the Complete pro-
tease inhibitor mixture from Roche (Mannheim, Germany);
BCA protein assay kit from Pierce; the 96-well plates from
Nunc and the transparent 96-well plates from Costar. [
35S]-
GTPgS, SteadyLite substrate, [
3H]-LTC4 and [
3H]-LTD4 were
purchased from Perkin Elmer; WGA-coupled SPA-beads from
Amersham Biosciences; the trans-reporter CREB-luciferase
assay was obtained from Stratagene (La Jolla, CA, USA); the
ImProm II Reverse Transcriptase kit from Promega; the SYBR
Premix Ex Taq RT-PCR kit from Takara Bio Inc. and the
MX3000p cycler from Stratagene.
Site-directed mutagenesis and cloning
All GPR17 constructs, CysLT1 and CysLT2 were inserted into a
modiﬁed pcDNA3 vector, kindly provided by Kate Hansen
(7TM-Pharma, Denmark), which contained an upstream
sequence encoding a haemagglutinin signal peptide fused to
the M1-FLAG tag. Cloning of the murine GPR17 was achieved
by nested PCR using genomic DNA from mice as template and
veriﬁed by sequencing.
Transfection and tissue culture
Both HEK293 and 1321N1 cells were grown in DMEM
adjusted to contain 4500 mg·L
–1 glucose, 10% FBS (fetal
bovine serum), 180 u·mL
–1 penicillin and 45 ug·mL
–1 strepto-
mycin (PenStrep) at 10% CO2 and 37°C. For CREB-luciferase
and ELISA assays, transient transfections were carried out
using Lipofectamine
TM 2000 reagent and the serum-free
medium OPTIMEM as described previously (Benned-Jensen
and Rosenkilde, 2008). Cells were always transfected in par-
allel for the CREB luciferase and ELISA assays. For membrane
preparations, transient transfections were performed using
the calcium precipitation method as described previously
(Rosenkilde et al., 1999).
Membrane preparation
Membranes were prepared from HEK293 and 1321N1 cells
transiently transfected with pcDNA3 vector control,
Differential functions of two GPR17 isoforms
T Benned-Jensen and MM Rosenkilde 1093
British Journal of Pharmacology (2010) 159 1092–1105hGPR17-L, hGPR17-S, mGPR17 and CysLT2 wt. The cells were
manually harvested with a rubber policeman in ice-cold PBS
and homogenized using a Dounce on ice. The homogenate
was centrifuged at 45 g for 3 min at 4°C. Subsequently, the
supernatants were collected and centrifuged at 47 800 g at
4°C. The resulting membrane pellets were resuspended in
20 mM HEPES buffer containing 2 mM MgCl2 and Complete
protease inhibitor mixture and kept at –80°C until subjected
to [
35S]-GTPgS binding experiments. The protein concentra-
tions in each preparation were determined using the BCA
protein assay kit.
[
35S]-GTPgS binding assay
[
35S]-GTPgS binding experiments were carried out in white
96-well plates using the SPA-based method. A volume of
membrane preparation (corresponding to 20 mg protein per
well) was diluted in assay buffer (50 mM HEPES, 3 mM MgCl2,
100 mM NaCl, 1 mM EGTA, 3 mM GDP, 10 mg·mL
–1 saponin
and Complete protease inhibitor mix, pH 7.4). [
35S]-GTPgS
(1250 Ci·mmol
–1, 12.5 mCi·mL
–1) diluted in assay buffer was
added to a ﬁnal concentration of 1 nM and incubated for 1 h
at 30°C. When used, LTD4 was added at 1 mM along with a
vehicle control (DMSO) at this step. Subsequently, WGA-
coupled SPA-beads was added (ﬁnal concentration of
2.8 mg·mL
–1) followed by 30 min incubation at room tem-
perature on a plate shaker. Finally, the plates were centrifuged
at 400 g for 5 min and the amount of radioactivity deter-
mined using a Top Count scintillation counter (Packard
Instruments). The level of non-speciﬁc binding was deter-
mined by adding unlabelled GTPgS at a ﬁnal concentration of
40 mM. All experiments were carried out at least three times
and in triplicates.
Competition binding assay
Competition binding experiments were carried out in trans-
parent 96-well plates employing [
3H]-LTC4 and [
3H]-LTD4 as
radioligands. A volume of membrane preparation (corre-
sponding to 25 mg protein per well) was diluted in binding
buffer (ﬁnal concentration: 50 mM Tris-HCl, 5 mM MgCl2,
100 mg·mL
–1 Bacitracin and Complete protease inhibitor
mix, pH 7.4). [
3H]-LTC4 or [
3H]-LTD4 (122.7 Ci·mmol
–1,
0.01 mCi·mL
–1) diluted in binding buffer was added to a ﬁnal
concentration of 0.4 nM and subsequently unlabelled LTC4
or LTD4 was added in the concentration range of 0.1 nM to
1 mM. Following 2 h incubation at room temperature, the
membranes were captured on Skatron 11731 FilterMATs using
a Skatron cell harvester and GF/C ﬁlters. The harvested mem-
branes were washed in buffer (50 mM Tris-HCl, 5 mM MgCl2
and 0.1% BSA) and dried for 30 min at 60°C. The amount of
radioactivity was determined using EcoScint
TM XR and
a Beckman scintillation counter. The speciﬁc binding
accounted for approximately 8% of total binding
(~1600 cpm). All experiments were carried out at least three
times and in duplicates.
cAMP response element binding protein trans-reporter
luciferase assay
The level of constitutive activity was determined using the
trans-reporter cAMP response element binding protein
(CREB)-luciferase assay according to the manufacturer’s rec-
ommendations. HEK293 cells were seeded at 35 000 cells per
well in 96-well plates and were transiently transfected the
following day with FLAG-tagged receptor constructs or
pcDNA3 at the indicated concentrations along with the trans-
activator plasmid pFA2-CREB and the reporter plasmid
pFRLUC at 6 ng per well and 50 ng per well respectively. In
some experiments, the cells were also co-transfected with the
chimeric G-protein, GaD6qi4myr (abbreviated Gqi4myr) at
30 ng per well (Kostenis, 2001). The CREB activity was deter-
mined 48 h after transfection using the SteadyLite substrate.
Brieﬂy, the cells were washed twice in Dulbecco’s PBS (0.9 mM
CaCl2, 2.7 mM KCl, 1.5 mM KH2PO4, 0.5 mM MgCl2, 137 mM
NaCl, and 8.1 mM Na2HPO4) and the luminescence measured
10 min after addition of the substrate using a TopCounter
(Packard). When used, forskolin (15 mM), UDP, UDP-glucose,
UDP-galactose (all in range of 10 nM to 100 mM), LTC4 or
LTD4 (0.1 nM to 1 mM) was added 5 h prior to substrate addi-
tion, while pertussis toxin (100 ng·mL
–1) was added 24 h
before substrate addition. For the antagonism test of Mon-
telukast and Ticlopidine, the compounds were given 15 min
prior to the agonists (i.e. 5 h and 15 min before substrate
addition), whereas the same two compounds, when tested for
inverse agonism, were given 24 h before substrate addition
(i.e. right after termination of transfection). Each receptor
construct was tested at least three times in quadruplicates.
Enzyme-linked immunosorbent assay
HEK293 cells were transiently transfected with the indicated
FLAG-tagged receptor constructs as described above; 48 h
after transfection, the cells were ﬁxed in 4% formaldehyde for
10 min, washed three times in TBS (50 mM Tris and 150 mM
NaCl, pH 7.6) and blocked for 30 min with TBS containing
2% BSA. Subsequently, the cells were incubated with mouse
anti-FLAG M1 antibody at 2 ug·mL
–1 for 2 h in TBS supple-
mented with 1% BSA and 1 mM CaCl2. After three washes in
TBS containing 1% BSA and 1 mM CaCl2, the cells were
incubated for 1 h with goat anti-mouse horseradish
peroxidase-conjugated antibody diluted 1:1000 in the same
buffer as the primary antibody. Following washing, the
immune reactivity was determined by addition of TMB
according to manufacturer’s instructions. All steps were
carried out at room temperature.
Quantitative real-time PCR
Total RNA from heart, kidney, total brain and eight different
brain regions (amygdala, cerebellar hemisphere, cerebellum,
frontal cortex, hippocampus, hypothalamus, putamen and
thalamus) were acquired from Ambion. cDNA was synthe-
sized from 1 ug of RNA using the ImProm II Reverse Tran-
scriptase kit and random hexamer primers. Quantiﬁcation of
hGPR17-L and -S transcript levels were performed using the
SYBR Premix Ex Taq RT-PCR kit and a MX3000p cycler.
Expression levels of b-actin were used for copy normalization.
All experiments were performed four times in triplicates. The
forward primers for the two GPR17 transcripts were isoform-
speciﬁc and did both span exon-exon junctions preventing
ampliﬁcation of contaminant genomic DNA, while the
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for hGPR17-L and 187 bp for hGPR17-S. The b-actin primers
did also span an exon-exon junction and gave an amplicon
length of 80 bp. The sequence of the primers were: forward
hGPR17-L: GCTGAAACTCTCAGGCTCTGAC, forward
hGPR17-S: CCAGCAGCTAGAGGCTCTGA, reverse hGPR17-
L/-S: GCCAGGGTATTGCCAACTAA, forward b-actin:
CGTCTTCCCCTCCATCGT and reverse b-actin: CGCCCAC
ATAGGAATCCTTC. Ampliﬁcations of the primer pairs were
validated using serial dilution of the total brain cDNA and
speciﬁcity by dissociation curve analysis being satisfactory in
all cases.
Antibody-feeding internalization assay
HEK293 cells were seeded on poly-L-lysine-coated coverslips
in six-well plates at 5 ¥ 10
5 cells per well. The following day
the cells were transfected with the indicated FLAG-tagged
receptor constructs at 150 ng per well using Lipofectamine
TM
2000 as described above. Forty-eight hours after transfection,
the cells were incubated in cold DMEM medium containing
mouse M1 anti-FLAG antibody at 2 mg·mL
–1 and incubated 1 h
at 4°C. After being washed in cold DMEM medium, the speci-
mens were either immediately ﬁxed in 4% paraformaldehyde
or incubated in pre-warmed DMEM medium containing
either vehicle (DMSO) or LTD4 at 1 mM at 37°C for 30 min, to
induce internalization, and then ﬁxed. Subsequently, the cov-
erslips were blocked with TBS containing 2% BSA. To speciﬁ-
cally detect labelled receptors still residing at the cell surface,
the cells were incubated with goat anti-mouse Alexa Flour
488-conjugated antibody diluted 1:1000 in TBS containing
1% BSA for 30 min. After being washed, the cells were perme-
abilized using TBS containing 1% BSA and 0.2% saponin for
30 min. To detect internalized labelled receptors, the cover-
slips were incubated with goat anti-mouse Alexa-Fluor 568-
conjugated antibodies diluted 1:1000 in TBS containing 1%
BSA for 30 min. Subsequent to washing, the specimens were
mounted in SlowFade Antifade reagent using nail polish as a
sealant. All steps following the internalization step were
carried out at room temperature. Mock transfected cells were
included to ensure no non-speciﬁc binding of any of the
antibodies.
Confocal microscopy
Confocal microscopy was performed using a LSM 510 laser
scanning unit coupled to an inverted microscope with a
63 ¥ 1.4 numerical aperture oil immersion Plan-Apochromat
objective (Carl Zeiss). Alexa-Fluor 488 was excited using an
argon-krypton laser (l=488 nm) and the emission collected
with a 505 nm long-pass ﬁlter. Images were recorded in
1024 ¥ 1024 pixels and averaged over 16 whole frame scans.
Statistical analysis
All statistical analyses were carried out using GraphPad Prism
software. EC50 and IC50 values were determined using non-
linear regression curve ﬁts. Differences in expression levels
(Figure 1D), expression ratios (Figure 2C), constitutive activ-
ity measured using [
35S]-GTPgS binding (Figure 4) and receptor
activation by LTD4 using [
35S]-GTPgS binding (Figure 7C) were
analysed by using Student’s t-test.
Results
The human GPR17 exists in two different isoforms, that are
both expressed at the cell surface
While searching the Ensembl Genome Browser we noticed
that GPR17 exists in two splice variations in human and
non-human primates. These differ only with respect of the
N-terminus, where the long human isoform, here referred to
as hGPR17-L, is 28 amino acids longer than the short, here
referred to as hGPR17-S (Figure 1A). The outline of the
mRNAs encoding the human receptor isoforms are depicted
in the inserts in Figure 2A,B. Initially, to test whether hGPR17
is expressed at the cell surface, we generated a fusion con-
struct of hGPR17-L and eGFP. The cellular localization of the
construct was evaluated using confocal microscopy in
HEK293 cells and, as GPR17 is mainly expressed in the brain,
1321N1 astrocytoma cells. In both cell lines, the receptor was
predominantly localized at the cell surface as seen for the
majority of endogenous 7TM receptors (Figure 1B,C). The
surface expression was conﬁrmed by an ELISA-based assay
employing N-terminal FLAG-tagged versions of both human
isoforms (Figure 1D). Thus, in HEK293 cells transiently trans-
fected with M1-GPR17-L and -S both were expressed at the
cell surface with the short isoform being present at sligthly
higher levels (Figure 1D). The expression levels were compa-
rable with that previously seen for other 7TM receptors, e.g.
the M1-FLAG tagged EBI2 receptor (Rosenkilde et al., 2006).
Isoform-speciﬁc analysis of GPR17 gene expression in brain,
heart and kidneys
Earlier studies of GPR17 gene expression in humans, rats and
mice have shown that the receptor is primarily expressed in
brain. In addition, minor expression has also been observed
in heart and kidney (Blasius et al., 1998; Ciana et al., 2006;
Lecca et al., 2008). However, these analyses were only quali-
tative (Northern blotting and end-point RT-PCR), performed
on whole organs and not isoform-speciﬁc. In order to obtain
a more detailed picture of the expression pattern, using quan-
titative RT-PCR, we determined the relative expression levels
of the two GPR17 isoforms in eight different brain regions as
well as whole brain, heart and kidney. The forward primers
were designed to span the exon2-exon3 junction and the
exon1-exon3 junction for hGPR17-L and hGPR17-S, respec-
tively, ensuring that the ampliﬁcations were isoform-speciﬁc,
while the reverse primer was shared ensuring similar
amplicon lengths (189 and 187 bp respectively) (inserts,
Figure 2A,B). All primer sequences are given in the Methods
section. The expression levels were normalized to that of
b-actin and presented relative to the normalized hGPR17-L
expression in whole brain.
As shown in Figure 2A,B, the expression patterns of
hGPR17-Land-Swereremarkablysimilarinthedifferentbrain
tissues. Thus, for both isoforms, the lowest expression was
observed in thalamus with gradually increasing expression
levels through the hypothalamus, cerebellum, amygdala,
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putamen. For both isoforms, the putamen region exhibited
relatively higher expression than in whole brain, while this
was also observed for hGPR17-S in hippocampus. Expression
levels equal to those in whole brain were seen in frontal cortex
and for hGPR17-L in hippocampus, whereas lower levels were
present in all other brain tissues for both isoforms in varying
degrees (Figure 2A,B). To facilitate a comparison of the expres-
sionlevelsofthetwoisoforms,theratiosofthesearepresented
in Figure 2C. In the brain, the short isoform was expressed at
much higher levels than the long and, given the similar
expression pattern, the ratios were largely similar. Thus, in
whole brain, hGPR17-S was expressed at approximately
10-fold higher levels than hGPR17-L, which was also observed
in hypothalamus, cerebellar hemisphere and frontal cortex.
Slightly lower ratios (compared with that in whole brain) were
observed in cerebellum and putamen. However, although sig-
niﬁcant, the differences are small with ratios of approximately
8inbothcases.Incontrast,considerablyhigherratiosof22,18
and 23 were observed in thalamus, amygdala and hippocam-
pusrespectively.Interestingly,thereversepicturewasobserved
inheartandkidney.Inbothtissues,hGPR17-Lwasexpressedat
higher levels compared with total brain (approximately seven-
and twofold respectively), while the opposite was the case for
hGPR17-S. In fact, no detectable expression was present in
kidneys for the latter (Figure 2A,B, right panels). Thus, in the
heart, hGPR17-L was expressed at approximately 12-fold
higher levels than hGPR17-S. Given the absence of hGPR17-S
expression in kidneys, the similar comparison was not appli-
cable for this organ (Figure 2C, right).
Figure 1 Primary structure and cell surface expression of hGPR17. (A) Serpentine model of hGPR17. The highly conserved residues among
rhodopsin-like 7TM receptors are indicated as black circles with white letters in each transmembrane helix and the conserved disulphide-bridge
between the extracellular loop 2 and the conserved cysteine residue in TM3 denoted as a stapled line. The 28 amino acids comprising the
longer N-terminus of the hGPR17-L splice variant are indicated as grey circles. (B) Expression of C-terminally eGFP-tagged hGPR17-L in
transiently transfected HEK293 cells as detected by confocal microscopy. (C) Expression of C-terminally eGFP-tagged hGPR17-L in transiently
transfected 1321N1 cells as detected by confocal microscopy. (D) Cell surface expression of FLAG-tagged hGPR17 isoforms in HEK293 cells
transiently transfected with hGPR17-L, -S or pcDNA3 vector control as measured by ELISA. The results represent mean  SEM of raw data from
three independent experiments performed in quadruplicates. *P < 0.05 by Student’s t-test. 7TM, seven transmembrane; hGPR17-L, long
GPR17 isoform.
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To examine whether both isoforms are functional, we initially
tested for putative signalling using the CREB reporter assay.
The activity of this transcription factor is primarily regulated
by the intracellular cAMP level via cAMP-regulated kinases
and consequently reﬂects the Gai or Gas coupling of a given
receptor when used as a reporter. In addition, kinases down-
stream of Gaq also mediate CREB activation (Shaywitz and
Greenberg, 1999). Gene-dosage experiments in transiently
transfected HEK293 cells demonstrated that both human iso-
forms of GPR17 inhibited a forskolin-induced CREB activity
with approximately 75% (Figure 3A,B). Importantly, empty
pcDNA3 vector (negative control) at similar doses did not
have any effect, indicating that both isoforms are constitu-
tively active through Gai, This was further corroborated by
administration of the Gai inhibitor pertussis toxin, which
abolished the effect in both cases (Figure 3A,B). Also, as
shown in Figure 3C, co-transfection with the chimeric
Ga-subunit Gqi4myr, resulted in dose-dependent increases in
Figure 2 Gene expression levels of the two hGPR17 isoforms and
the ratio of these in brain, heart and kidney. (A) Levels of hGPR17-L
transcript in total brain and eight different brain regions (left panel)
and kidney and heart (right panel). The expression levels are given
relative (in fold) to that in total brain, which is indicated by the
stippled line. The insert is a schematic representation of the hGPR17-L
mRNA species. Translated and untranslated regions are indicated in
black and white respectively. The isoform-speciﬁc forward primer
spans the exon 2–3 border and is depicted in black, whereas the
shared reverse primer is depicted in white. (B) Levels of hGPR17-S the
same tissues as in (A). The expression levels are given relative (in fold)
to that of hGPR17-L in total brain (stippled line). No expression was
detected in kidney. The insert is a schematic representation of the
hGPR17-S mRNA species. Translated and untranslated regions are
indicated in grey and white respectively. The isoform-speciﬁc forward
primer spans the exon 1–3 border and is depicted in grey, whereas
the shared reverse primer is depicted in white. (C) Ratio of hGPR17-S
and -L expression levels from (B) and (A) respectively. The stippled
line indicates a ratio of 1, i.e. equal expression levels. Ratios signiﬁ-
cantly different from that in total brain are indicated; *P < 0.05,
**P < 0.01 and ***P < 0.0001 (Student’s t-test). Given the absence of
hGPR17-S expression in kidney the ratio is not calculable in this
instance. hGPR17-L, long GPR17 isoform; hGPR17-S, short GPR17
isoform.
Figure 3 Constitutive signalling (A–C) and surface expression (D) of
the two hGPR17 isoforms. (A) Inhibition of forskolin-induced CREB
activity (abbreviated fsk-CREB act.) in HEK293 cells transfected with
hGPR17-L or pcDNA3 vector control in the presence or absence of
pertussis toxin (ptx, 100 ng·mL
–1). The cells were transiently trans-
fected with CREB-Luc reporter vector and FLAG-tagged hGPR17-L or
pcDNA3 at 0, 5, 15 and 25 ng per well. Production of cAMP was
stimulated with 15 mM forskolin. The results are given relative to the
activity at 0 ng per well in % and are presented as mean  SEM from
at least four independent experiments performed in quadruplicates.
(B) Inhibition of forskolin-induced cAMP production in HEK293 cells
transfected with FLAG-tagged hGPR17-S or pcDNA3; performed and
presented as in (A). Statistical analyses of data in (A) and (B):
***P < 0.0001 (Student’s t-test). (C) CREB activity in HEK293 cells
transiently transfected with the chimeric Ga subunit Gqi4myr, CREB-
Luc reporter vector and hGPR17-L, -S or pcDNA3 at 0, 5, 15 and
25 ng per well. The results are given relative to the activity at 0 ng per
well in % and are presented as mean  SEM from four independent
experiments performed in quadruplicates. (D) Cell surface expression
of FLAG-tagged hGPR17-L and -S in HEK293 cells as measured by
ELISA. The cells were transiently transfected with hGPR17-L, -S or
pcDNA3 in parallel with the experiments presented in (C). The results
represent mean  SEM of raw data from four independent experi-
ments performed in quadruplicates. CREB, cAMP response element
binding protein; hGPR17-L, long GPR17 isoform; hGPR17-S, short
GPR17 isoform.
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receptors but transduces a Gaq signal (Kostenis, 2001). Thus,
the observed increase in CREB activity upon hGPR17-L and -S
transfection substantiates the notion that both human GPR17
isoforms couple to and signal constitutively via Gai.I nt h e
absence of forskolin, increasing doses of hGPR17-L and -S, as
opposed to the positive control ORF74, did not result in any
increase in CREB activity or differ from that of pcDNA3 trans-
fected cells (Figure S1A–D) demonstrating that neither of the
hGPR17 isoforms signals constitutively through either Gas or
Gaq. We also tested putative constitutive activation of the
transcription factors NF-kB and NFAT; neither, however,
was activated dose-dependently by any of the isoforms
(Figure S1E–F). To ensure that both receptors were present at
the cell surface, ELISA was performed on HEK293 cells trans-
fected in parallel with the functional experiments (Figure 3D).
Both isoforms were expressed well with hGPR17-S being
present at approximately 30–40% higher levels than
hGPR17-L at corresponding doses (Figure 3D). The above-
mentioned experiments were all carried out using the
M1-tagged receptor constructs in order to compare receptor
activity with receptor expression in parallel (Figure 3). The
M1-tag did not inﬂuence receptor activity, as similar levels of
constitutive activity were obtained for the untagged receptor
constructs (data not shown).
As activation of a transcription factor is an event relatively
far downstream from the initial receptor activation and can
be inﬂuenced by a variety of factors, we decided to assess the
constitutive activity of the two hGPR17 isoforms using the
GTPgS assay. The measurement of [
35S]-GTPgS binding was
performed on membranes puriﬁed from HEK293 and 1321N1
cells transfected with hGPR17-L, -S or vector control
(pcDNA3). Prior to membrane puriﬁcation, proper cell surface
expression of the receptors was veriﬁed by ELISA experiments
with the relative expression levels being similar to those
shown in Figure 3D (data not shown). As presented in
Figure 4A, [
35S]-GTPgS binding was signiﬁcantly elevated in
membranes from HEK293 cells containing either of the
hGPR17 isoforms compared with membranes from empty
pcDNA3 vector transfected cells. In both cases, an approxi-
mately threefold increase was observed with no signiﬁcant
difference between the two isoforms (Figure 4A). To conﬁrm
the suggestion that hGPR17-L and -S are Gai-coupled, [
35S]-
GTPgS binding was performed on membranes puriﬁed from
hGPR17-L-, -S- or pcDNA3-transfected cells that had been
exposed to pertussis toxin (100 ng·mL
–1). Importantly, the
presence of this toxin completely reduced the level of [
35S]-
GTPgS binding to hGPR17-L and -S membranes to the level
observed in pcDNA3 control membranes (Figure 4A). As
hGPR17-S mainly is expressed in the brain, [
35S]-GTPgS
binding was also evaluated in membranes from transiently
transfected 1321N1 astrocytoma cells. As shown in Figure 4B,
the presence of either isoform led to a signiﬁcant increase in
[
35S]-GTPgS binding compared with pcDNA3-transfected
membranes. The magnitude of this increase, however, was
less marked than in membranes from HEK293 cells, which
probably reﬂects the lower transfection efﬁciency of 1321N1
cells compared with HEK293 cells (as judged by confocal
microscopy; data not shown). As observed in HEK293 cells,
the increase in [
35S]-GTPgS binding was abolished upon treat-
ment with pertussis toxin (Figure 4B), corroborating the
observation that both isoforms are Gai-coupled. In addition,
the basal binding to pcDNA3-transfected membranes was
reduced upon administration of pertussis toxin, suggesting
that 1321N1 cells express endogenous constitutively active
Gai-coupled receptors.
To determine whether the murine GPR17 displays a similar
signalling phenotype to the human homologue, we carried
out the exact same experiments as described above for this
receptor. As shown in Figure S2, mGPR17 was indeed also
constitutively active through Gai and in this regard com-
pletely similar to its human counterpart.
The uracil nucleotides UDP-glucose, UDP-galactose and UDP
activate hGPR17-S and -L with different potencies
GPR17 was recently deorphanized as the target for two chemi-
cally very distinct types of agonists, namely uracil nucleotides
and cysteinyl leukotrienes (Ciana et al., 2006; Lecca et al.,
2008; Parravicini et al., 2008). The former group of ligands
(consisting of UDP-glucose, UDP-galactose and UDP) has
been found to have potencies in the mM range and the latter
group (LTC4 and LTD4) in the nM range (Ciana et al., 2006;
Lecca et al., 2008; Parravicini et al., 2008). However, these
studies included the rat and murine GPR17 and the
hGPR17-S, but not hGPR17-L. To determine whether the
ligands also activated the long isoform, we conducted dose–
response experiments in transiently transfected HEK293 cells,
using CREB activity as readout. For the uracil nucleotides, we
included the hP2Y14 and the hP2Y6 receptors as positive
controls for the UDP-sugars and UDP respectively. As seen in
Figure 5, UDP-glucose, UDP-galactose and UDP activated
hGPR17-S dose-dependently with EC50 values of 1.2, 0.3 and
1.6 mM, respectively, which closely match those previously
reported for this isoform (Ciana et al., 2006). However, these
ligands were much less potent at hGPR17-L. Thus, for the
Figure 4 Constitutive signalling of hGPR17-L and -S as measured by
[
35S]-GTPgS binding. (A) [
35S]-GTPgS binding to membranes isolated
from HEK293 cells transiently transfected with FLAG-tagged
hGPR17-L, -S or pcDNA3. The cells were cultured in the absence
(solid columns) or presence (open columns) of 100 ng·mL
–1 pertussis
toxin (ptx). The level of binding to pcDNA3-membranes is indicated
by the stippled line. The results represent mean  SEM of raw data
from four independent experiments performed in triplicates.
**P < 0.01 by Student’s t-test. (B) [
35S]-GTPgS binding to membranes
isolated from 1321N1 cells transiently transfected with hGPR17-L, -S
or pcDNA3; performed and presented as in (A). *P < 0.05, **P < 0.01
by Student’s t-test. hGPR17-L, long GPR17 isoform; hGPR17-S, short
GPR17 isoform.
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Assuming equal efﬁcacies for both isoforms, UDP-glucose
(Figure 5A) and UDP-galactose (Figure 5C) were approxi-
mately 50- and 170-fold more potent for hGPR17-S as
compared with hGPR17-L respectively. Contrary to the UDP-
sugars, UDP did not activate hGPR17-L at concentrations up
to 100 mM (Figure 5E). In all cases, the positive controls were
activated by the ligands with EC50 values matching those
previously reported (Communi et al., 1996; Chambers et al.,
2000) (Figure 5B, D and F). In contrast, the efﬁcacies were
slightly lower (1.4-fold lower for the UDP-sugars and 2.4-fold
lower for UDP) on GPR17-S (Figure 5A, C and E) compared
with the corresponding efﬁcacies on the positive controls
(Figure 5B, D and F). In order to determine whether the con-
stitutive nature of GPR17 was the reason behind this pheno-
type (due to putative saturation of intracellular signalling
pathways), we repeated all dose–response experiments in cells
expressing lower levels of receptor (by lowering the receptor
DNA during transfection from 15 ng per well, to 5 and 1 ng
per well). No increases in the efﬁcacies were observed under
these settings, indicating that the slightly lower efﬁcacies are
not an artifact of the increased basal receptor activity.
The above-mentioned experiments were all carried out
using the M1-tagged receptor constructs. In order to assure
that the N-terminal M1-tag was not affecting ligand-binding,
we tested the same ligands on untagged GPR17-S and
GPR17-L, and found that the M1-tag had no effect (data not
shown). In conclusion, these results reveal a functional dif-
ference between the two isoforms. In turn, this aligns well
with the differential expression pattern presented in Figure 2
and supports the notion that each isoform probably has a
tissue-speciﬁc role.
As the activation of GPR17 by UDP ligands has previously
been shown to be antagonized by several P2Y compounds
(including a P2Y12 antagonist) (Pugliese et al., 2009), we
decided to test whether the P2Y12 antagonist Ticlopidine had
any inverse agonistic or antagonistic effects on GPR17.
However, Ticlopidine did not suppress the constitutive activ-
ity of any of the hGPR17 isoforms (Figure 6A) or antagonize
the activation by UDP or UDP-glucose (Figure 6B) as opposed
to that seen in the MeSADP-mediated activation of hP2Y12 in
the parallel control experiment (Figure 6C).
The cysteinyl leukotrienes LTD4 and LTC4 do not activate
or bind to hGPR17-L or -S
As mentioned earlier, the short isoform of GPR17 has also
been reported to be activated by the cysteinyl leukotrienes
LTC4 and LTD4 with EC50 values in the nM range (Ciana et al.,
2006; Lecca et al., 2008). Analogous to the uracil nucleotides,
we wanted to assess whether the cysteinyl leukotrienes also
activate hGPR17-L, initially focusing on LTD4. However, con-
trary to previous ﬁndings, LTD4 did not activate any of the
human isoforms in transiently transfected HEK293 cells,
using CREB activity as read out (Figure 7A). Both receptors
were present at the cell surface, as evident by the apparent
constitutive activity when compared with pcDNA3 trans-
fected cells (Figure 7A). In contrast to this observation, in the
parallel control experiment LTD4 dose-dependently activated
CysLT2 with an EC50 value of 3.1 nM (Figure 7B). Similarly, in
the GTPgS assay, LTD4 at 1 mM did not activate either of the
isoforms, whereas it resulted in a signiﬁcant increase in [
35S]-
GTPgS binding in membranes from CysLT2-transfected
HEK293 cells (Figure 7C). The magnitude of this relatively
small increase is probably due to the endogenous stoichiom-
e t r yo fG a-subunits, as the GTPgS assay is most suited for
Gai-coupled receptors (such as GPR17) compared with Gas-o r
Gaq-coupled receptors (such as CysLT2) given the lower
Figure 5 Uracil nucleotide ligands activate hGPR17-L and -S with
different potencies. (A) Activation of FLAG-tagged hGPR17-L and -S
by UDP-glucose in transiently transfected HEK293 cells. The cells
were transfected with Gqi4myr, CREB-Luc reporter plasmid and
receptor or pcDNA3 at 15 ng per well. The results are corrected for
background (pcDNA3-transfected cells) and given as % relative to
the activity in absence of the ligand. The data represent mean  SEM
of four independent experiments performed in quadruplicates. The
EC50 of the hGPR17-S response is indicated by the stippled line.
(B) Activation of hP2Y14 by UDP-glucose in transiently transfected
HEK293 cells; performed and presented as in (A). (C) Activation of
FLAG-tagged hGPR17-L and -S by UDP-galactose in transiently trans-
fected HEK293 cells; performed and presented as in (A). (D) Activa-
tion of hP2Y14 by UDP-galactose in transiently transfected HEK293
cells; performed and presented as in (A). (E) Activation of FLAG-
tagged hGPR17-L and -S by UDP in transiently transfected HEK293
cells; performed and presented as in (A). (F) Activation of hP2Y6 by
UDP in transiently transfected HEK293 cells; performed and pre-
sented as in (A) with the exception that Gqi4myr was not
co-transfected in this case. CREB, cAMP response element binding
protein; hGPR17-L, long GPR17 isoform; hGPR17-S, short GPR17
isoform.
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gan, 2003).
Given these results, we decided to carry out homologous
competition binding to assess whether LTD4 binds to
hGPR17-L and -S. This was performed on the same mem-
branes used for the GTPgS assay, ensuring that all of the
receptors were present in the membranes (assessed by ELISA)
and were functional (assessed by [
35S]-GTPgS binding). As
shown in Figure 7D, [
3H]-LTD4 bound to HEK293 membranes
harbouring CysLT2 and was dose-dependently displaced by
unlabelled LTD4 with an IC50 of 10.3 nM. In contrast to this,
no binding was observed for membranes containing
hGPR17-L or -S, demonstrating that LTD4 does not bind to
any of these isoforms. To ensure that the lack of binding was
not a matter of cell type, we repeated the binding experiment
in membranes from 1321N1 cells, and as in HEK293 cells, no
binding was observed to membranes containing either of the
isoforms (data not shown). Analogous to the functional
studies, the same experiments were carried out for mGPR17
and gave the same results as described above for the human
counterparts (Figure S2).
Given that the CysLT1 selective antagonist Montelukast has
previously has been suggested to function as an antagonist on
GPR17 (Pugliese et al., 2009), we decided to test for inverse
agonism on both GPR17-isoforms of this compound.
However, as shown in Figure 7E, Montelukast did not sup-
press the constitutive activity of either of the isoforms. As a
control, the antagonizing effect of this compound on the
LTC4-mediated CysLT1 activation was evaluated in parallel
and gave an IC50 value in agreement with previous reports
(Figure 7F).
Finally, we determined whether LTD4 stimulates internal-
ization of GPR17, as this is a hallmark of agonist-induced
activation of 7TM receptors. To do this, we employed an
antibody feeding internalization assay using CysLT2 as a posi-
tive control (Figure 8). Initially, cell surface expressed recep-
tors were labelled with primary antibody and subsequently
incubated with LTD4 to induce internalization. Following
this, labelled receptors still residing at the surface and those
internalized were separately detected using two different
ﬂuorophore-conjugated secondary antibodies before and after
permeabilization respectively. In turn, a comparison of these
two receptor populations gives a qualitative measurement of
the apparent internalization rate. As shown in Figure 8B
(lower panels), virtually all labelled CysLT2 receptors were
internalized after 30 min incubation in the presence of 1 mM
LTD4 as virtually no labelled receptors were detected before
permeabilization. That this was a speciﬁc event was evident
by the notion that only a small amount of (constitutive)
internalization happened when vehicle (DMSO) was present
(Figure 8B, upper panels). Contrary to CysLT2,L T D 4 did not
induce internalization of hGPR17-L as only constitutive inter-
nalization was observed when either this or vehicle was
present with no apparent differences in the internalization
pattern between these conditions (Figure 8A). In conclusion,
these results align well with the observation that LTD4 neither
activates nor binds to GPR17.
Furthermore, we carried out similar dose–response and
competition binding experiments with LTC4. As shown in
Figure S3, LTC4 did not activate or bind to hGPR17-L, -S or
mGPR17, whereas this was readily observed for CysLT2. Thus,
in our eyes, and contrary to previous reports (Ciana et al.,
2006; Lecca et al., 2008) and in line with the recent work of
Maekawa et al. (Maekawa et al. 2009), the cysteinyl leuko-
trienes LTD4 and LTC4 are not agonists of GPR17.
Discussion
In the present study, we characterized the 7TM receptor
GPR17. First, we present a detailed expression analysis of the
two human isoforms, hGPR17-L and -S, in several brain
regions as well as heart and kidney. Second, we showed that
hGPR17-L, -S and the murine GPR17 are constitutively active
through Gai. Third, we demonstrated that uracil nucleotide
ligands activate the two human isoforms with very different
potencies. Finally, we demonstrated that this receptor, previ-
ously reported to be activated by cysteinyl leukotrienes (Ciana
et al., 2006; Lecca et al., 2008), is not activated, internalized or
bound by these molecules.
Figure 6 Ticlopidine does not display inverse agonism or antagonism at hGPR17 isoforms. (A) Putative inverse agonism of Ticlopidine.
HEK293 cells were transiently transfected with Gqi4myr, CREB-Luc reporter plasmid and receptor or pcDNA3 at 15 ng per well.and incubated
with the ligand in varying concentrations. The results are corrected for background (pcDNA3-transfected cells) and given as % relative to the
activity in absence of the ligand. The data represent mean  SEM of two independent experiments performed in quadruplicates. (B) Putative
antagonism of Ticlopidine. HEK293 cells were transfected as described in (A) and incubated with agonist (UDP or UDP-glucose) at 10 mM and
Ticlopidine in varying concentrations. The results are presented as in (A). (C) hP2Y12 control. HEK293 cells were transfected as described in
(A) and were incubated with the agonist MeSADP at 10 nM and Ticlopidine in varying concentrations. The results are presented as in (A). CREB,
cAMP response element binding protein; hGPR17, GPR17 isoform.
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The constitutive activity of the two human isoforms and the
murine homologue was investigated both directly at the level
of G protein activation using [
35S]-GTPgS binding (Figure 4)
and further downstream by measuring CREB transcriptional
factor activity (Figure 3). We found that all three constructs
signalled constitutively as evident by (i) the substantial
increase in [
35S]-GTPgS binding to membranes containing
either of the receptors compared with membranes from
pcDNA3-transfected cells (Figure 4); (ii) the dose-dependent
inhibition of forskolin-induced CREB activity (Figure 3A,B);
and (iii) the increase in CREB activity upon co-expression of
the chimeric Ga protein subunit Gqi4myr (Figure 3C). This
constitutive signalling was mediated via Gai as both [
35S]-
GTPgS binding and CREB activity inhibition were highly sen-
sitive to pertussis toxin.
Constitutive activity per se is not an unusual phenomenon
among endogenous 7TM receptors. Notable examples are the
ghrelin and the melanocortin 4 receptor, which have well
characterized constitutive signalling patterns(Holst et al.,
Figure 7 LTD4 does not activate or bind to either of the hGPR17
isoforms. (A) Response to LTD4 in HEK293 cells transiently transfected
with Gqi4myr, CREB-Luc reporter plasmid and FLAG-tagged
hGPR17-L, -S or pcDNA3 at 15 ng per well. The results represent
mean  SEM of raw data from four independent experiments per-
formed in quadruplicates. (B) Activation of FLAG-tagged CysLT2 by
LTD4; performed and presented as in (A). The EC50 value is indicated
by the stippled line. (C) Effects of LTD4 1 mM (open columns) or
vehicle (DMSO, solid columns) on [
35S]-GTPgS binding to membranes
isolated from HEK293 cells transiently transfected with FLAG-tagged
hGPR17-L, -S, CysLT2 or pcDNA. The data represent mean  SEM of
raw data from four independent experiments performed in tripli-
cates. *P < 0.05 by Student’s t-test. (D) Homologous competition
assay for [
3H]-LTD4 binding to the membranes from HEK293 cells
transiently transfected with hGPR17-L, -S, CysLT2 or pcDNA3; these
were similar to those used in (C). The data represent mean  SEM of
raw data from four independent experiments performed in dupli-
cates. ipThe IC50 value for CysLT2 is indicated by the stapled line.
(E) Putative inverse agonism of Montelukast. HEK293 cells were trans-
fected as in (A) and incubated with Montelukast in varying concen-
trations. The results represent mean  SEM of three independent
experiments performed in triplicates and are given as % relative to
the activity in absence of the ligand. (F) CysLT1 control. HEK293 cells
were transfected as described in (A) and incubated with LTC4 at 1 nM
and Montelukast at varying concentrations. The EC50 value is indi-
cated by the stippled line. CREB, cAMP response element binding
protein; hGPR17-L, long GPR17 isoform; hGPR17-S, short GPR17
isoform.
Figure 8 LTD4 does not induce internalization of hGPR17-L.
(A) Internalization of FLAG-tagged hGPR17-L in transiently trans-
fected HEK293 cells in the presence of vehicle (DMSO, upper panels)
or LTD4 at 1 mM (lower panels). Receptors at the surface were labelled
with M1 anti-FLAG antibody prior to internalization. Subsequent to
this, labelled receptors still residing at the cell surface were detected
before permeabilization (green, left) and internalized receptors after
(red, middle) with two different secondary antibodies and analysed
by confocal microscopy. Merged images are presented to the right.
(B) Internalization of FLAG-tagged CysLT2 in the presence of vehicle
or LTD4; performed and presented as in (A). Scale bars denote 5 mM.
hGPR17-L, long GPR17 isoform.
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receptors exhibit constitutive signalling; these include GPR3,
-6, -12, -20, -39 and EBI2 (Holst et al., 2004; Rosenkilde et al.,
2006; Tanaka et al., 2007; Hase et al., 2008). Historically, the
concept of constitutive activity has been questioned by pri-
marily two factors: heterologous over-expression and the pos-
sible presence of agonists in the medium, both of which can
result in apparent ligand-independent signalling. In the case
of GPR17, over-expression does not seem to play a signiﬁcant
part as neither the Gaq-coupled CysLT2 nor the Gai-coupled
CXCR4 elicit dose-dependent constitutive CREB activity
when expressed at similar levels to hGPR17-L, -S or mGPR17
(Figure S1). This is further corroborated by the equal levels of
[
35S]-GTPgS binding to membranes isolated from either
CysLT2- or pcDNA3-transfected cells (Figure 7C). The presence
of an agonist in the medium also seems unlikely as the con-
stitutive activity of GPR17 was observed with two assay-types
(both membrane and whole cell-based) in two different cell-
lines, using two different media (Figures 3 and 4).
With regard to the constitutive activity of GPR17, it is
interesting to note that many neurologically expressed 7TM
receptors exhibit constitutive activity. This includes, among
others, the receptors targeted by the neurotransmitters mela-
tonin, dopamine, acetylcholine, opioid peptides and
glutamate (Seifert and Wenzel-Seifert, 2002). In turn, this
indicates that the constitutive activity of these receptors
serves to support basal neuronal activity. Also, many of the
orphan receptors expressed in the brain are constitutively
active. This includes among others the Gas-coupled GPR3, -6
and -12, for which it was recently shown that their constitu-
tive activity promotes neurite outgrowth by up-regulation of
cAMP levels (Tanaka et al., 2007). It is well known that the
endogenous cAMP level regulates several processes in neu-
rones including neurite outgrowth and axonal regeneration.
Thus, in this regard, GPR17 (and other constitutively active
Gai-coupled receptors) could potentially balance the action of
constitutively active Gas-coupled receptors in such processes
via Gai. As the level of constitutive activation is proportional
to the number of receptors on the cell surface, the intracellu-
lar cAMP level is in part regulated by the relative expression
levels of the Gas- and Gai-coupled receptors. Notably, in two
rodent models of ischaemic damage (Ciana et al., 2006; Lecca
et al., 2008) and a model of spinal cord injury (Ceruti et al.,
2009), GPR17 expression is up-regulated. Given the constitu-
tive activity observed in the present study, this up-regulation
would result in decreased cAMP levels, which could, by inhib-
iting outgrowth and regeneration, contribute to the neuronal
damage.
Different expression patterns of GPR17 isoforms
Our ﬁnding that hGPR17-S is the principal isoform in brain
(Figure 2) is consistent with the reported expression pattern of
rat and mice GPR17 (that are homologous to the short human
isoform) (Blasius et al., 1998; Ciana et al., 2006; Lecca et al.,
2008). Surprisingly, we found that the long isoform hGPR17-L
is expressed at higher levels in heart and kidneys compared
with brain. Importantly, compared with the short isoform,
hGPR17-L is expressed at much higher levels in the heart, and
in the kidneys (with no detectable expression of hGPR17-S in
the latter) indicating that hGPR17-S plays a principal role in
the brain (like r- and mGPR17), while hGPR17-L probably
adopts this role in the heart and kidneys (Figure 2). This
differential expression proﬁle suggests tissue-speciﬁc roles in
humans and other primates. Inherently, the existence of 7TM
receptor splice variants is puzzling and given the numerous
7TM receptor subfamilies, they seem somewhat superﬂuous.
For example, although the a-adrenoceptor subfamily har-
bours six members (a1A,- 1B,- 1D and a2A,- 2B,- 2C) the a1A subtype
exists (as annotated in the Ensemble Genome Browser) in 10
different splice variants. However, although our understand-
ing of splice variants is still limited, their relevance is under-
lined by accumulating data showing differences in both
function as well as spatial and temporal expression (Kilpatrick
et al., 1999). For example, different tissue distributions have,
apart from the present study of GPR17, been demonstrated for
the mGluR7a and -b among others. Thus, using isoform-
speciﬁc antibodies, Shigemoto et al. showed that the expres-
sion of mGluR7a was markedly different from that of
mGluR7b in the rat hippocampus (Shigemoto et al., 1997).
The same phenomenon has been observed for splice variants
of CRF2, for which it has been shown that the a-variant is
much more broadly expressed than the b- and g-variants
(Kostich et al., 1998). Direct demonstrations of the function
of 7TM receptor splice variants in vivo are few. However, the
two isoforms of the dopamine D2 receptor have been shown
to play different roles. Speciﬁcally, it was demonstrated, by
knocking out the long isoform of the D2 receptor in mice,
that this isoform mainly works at postsynaptic locations,
whereas the short isoform functions at presynaptic sites
(Usiello et al., 2000). During revision of this manuscript, a
report regarding the two same hGPR17 isoforms was pub-
lished. As opposed to the results presented in this study, the
gene expression of the long isoform was primarily restricted
to different brain regions and was not detected in heart or
kidney. A possible explanation for this discrepancy could be
that the forward primer used in the study by Pugliese et al.
(2009), by spanning the exon 1–2 border, only detects one out
of the three different mRNA species that encodes hGPR17-L.
On the contrary, the forward primer used in this study was
designed to detect all three species, thus giving a more com-
prehensive picture of the expression pattern of the long
isoform.
Different functional properties of GPR17 isoforms
Besides differences in tissue distribution, functional differ-
ences have also been identiﬁed for a range of 7TM splice
variants. Among others this includes variations in G protein
coupling and selectivity, ligand-binding proﬁles and internal-
ization pattern (Kilpatrick et al., 1999). Although the majority
of splice variations result in differences between the length of
the intracellular loops or the C-terminus, a substantial
number results in changes in the length of the N-terminus (as
seen for GPR17) and/or sequence (Kilpatrick et al., 1999). This
includes, among others, the cannabinoid receptor 1 (CB1)
(Rinaldi-carmona et al., 1996), the CRF2 (Kostich et al., 1998),
cholecystokinin CCKB (Miyake, 1995) and the PACAP receptor
(Pantaloni et al., 1996). Splice variants that differ by their
N-terminus tend to be affected primarily at the level of ligand
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activated less potently by their cognate agonists than their
long counterparts. This is especially true for 7TM receptors
that are activated by large peptides or proteins, which bind to
extracellular epitopes often including the N-terminus. The
CCKB receptor is a good example of this phenomenon, as
truncation of its N-terminus reduces its afﬁnity for both
gastrin and CCK-8 (Miyake, 1995). This is further corrobo-
rated by a recent study of the chemokine receptor CCR1
demonstrating that the binding of the CCL-3 and -5 chemok-
ines is highly dependent on an intact N-terminus (Jensen
et al., 2008).
In the case of GPR17, the reverse pattern is observed. Thus,
the longer isoform is only poorly (and in the case of UDP not
at all) activated by uracil nucleotides, whereas the short
isoform is activated with similar potencies, but slightly lower
efﬁcacies compared with the nucleotide receptors P2Y6 and
P2Y14 (Figure 5). The molecular mechanism responsible for
this difference remains to be identiﬁed. However, a similar
observation has been noted for N-terminal splice variants of
the PACAP receptor, where the short isoform is activated more
potently by the neuropeptides PACAP-27 and -38 (Pantaloni
et al., 1996). The endogenous ligand that activates hGPR17-L
is still to be identiﬁed, and given the low efﬁcacies observed
for uracil nucleotides on GPR17-S it is questionable whether
these ligands are, in fact, the most important endogenous
ligands. The longer N-terminus might render hGPR17-L
capable of binding other ligand types, e.g. proteins or large
peptides. Another possibility is that hGPR17-L does not have
a ligand at all. Putatively, the receptor activity could be regu-
lated at the expression level as the constitutive activity is
proportional to this, as suggested for, for example, the orphan
7TM receptor EBI2 (Rosenkilde et al., 2006). This could like-
wise be the case for Cpr2 as it was recently shown that the
expression of this constitutively active receptor is induced
after cell-cell fusion during the mating event in Cryptoccoccus
neoformans (Hsueh et al., 2009). The notion that many con-
stitutively active receptors are still orphan despite deorphani-
zation projects in both industry and academia suggests that
this is a possibility.
In conclusion, the discovery and elucidation of the consti-
tutive activity of the two human GPR17 isoforms along with
their differential expression and ligand-binding proﬁles add
new information to this receptor. In turn, it opens up the
possibility of selective drug targeting and also illustrates well
that 7TM receptor splice variants should be considered impor-
tant, as their pharmacological proﬁles and sites of action may
differ.
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online version of this article:
Figure S1 (A) The Gaq-coupled CysLT2 is not constitutively
active. HEK293 cells were transiently transfected with CREB-
Luc reporter plasmid and FLAG-tagged CysLT2 or pcDNA3 at
0, 5, 15 and 25 ng per well. The results are given relative to the
activity at 0 ng per well in percent and are presented as
mean  SEM from three independent experiments performed
in quadruples. (B) The Gai-coupled CXCR4 is not constitu-
tively active. HEK293 cells were transiently transfected with
Gqi4myr, CREB-Luc reporter plasmid and FLAG-tagged
CXCR4 or pcDNA3 at 0, 5, 15 and 25 ng per well. The results
are given relative to the activity at 0 ng per well in percent
and are presented as mean  SEM from three independent
experiments performed in quadruples. (C) ORF74 and EBI2
display constitutive activity. For EBI2, HEK293 cells were tran-
siently transfected with Gqi4myr, CREB-Luc reporter plasmid
and FLAG-tagged EBI2 or pcDNA3 at 0, 5, 15 and 25 ng per
well. For the ORF74, the experiment was performed the same
way but without presence of Gqi4myr. The results are given
relative to the activity at 0 ng per well in percent and are
presented as mean  SEM from three independent experi-
ments performed in quadruples. (D) Cell surface expression of
CysLT2 and CXCR4. HEK293 cells were transiently trans-
fected in the same way and in parallel to A and B. Cell surface
expression of the receptors were measured by ELISA and pre-
sented relative to 0 ng per well in percent as mean  SEM
(E) hGPR17-L is not constitutively active via NFAT. HEK293
cells were transiently transfected with NFAT-Luc reporter
plasmid and FLAG-tagged ORF74, hGPR17-L or pcDNA3 at 0,
5, 15 and 25 ng per well. The results are given relative to the
activity at 0 ng per well as mean  SEM of raw data from
three independent experiments performed in quadruples.
(F) hGPR17-L is not constitutively active via NFkB. HEK293
cells were transiently transfected with NFkB -Luc reporter
plasmid and FLAG-tagged ORF74, hGPR17-L or pcDNA3 at 0,
5, 15 and 25 ng per well. The results are given relative to the
activity at 0 ng per well as mean  SEM of raw data from
three independent experiments performed in quadruples.
Figure S2 mGPR17 is constitutively active through Gai.
(A) Inhibition of forskolin-induced CREB activity in HEK293
cells transfected with mGPR17 or pcDNA3 vector control in
the presence or absence of pertussis toxin (ptx, 100 ng/mL).
The cells were transiently transfected with CREB-Luc reporter
vector and FLAG-tagged mGPR17 or pcDNA3 vector control
at 0, 5, 15 and 25 ng per well. Production of cAMP was
stimulated with 15 mM forskolin. The results are given relative
to the activity at 0 ng per well in percent and are presented as
mean  SEM from three independent experiments performed
in quadruples. The stapled line indicates the level of inhibi-
tion by hGPR17-L. (B) CREB activity in HEK293 cells tran-
siently transfected with the chimeric Ga subunit Gqi4myr,
CREB-Luc reporter vector and FLAG-tagged mGPR17 or
pcDNA3 vector control at 0, 5, 15 and 25 ng per well. The
results are given relative to the activity at 0 ng per well in
percent and are presented as mean  SEM from three inde-
pendent experiments performed in quadruples. The stapled
line indicates the activity of hGPR17-L. (C) Cell surface
expression of FLAG-tagged mGPR17 in HEK293 cells as mea-
sured by ELISA. The cells were transiently transfected with
mGPR17 or pcDNA3 in parallel with the experiments pre-
sented in B. The results represent mean  SEM of raw data
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druples. The stapled line indicates the level of cell surface
expression of hGPR17-L. (D) [
35S]GTPgS binding to mem-
branes isolated from HEK293 cells transiently transfected with
FLAG-tagged mGPR17 or pcDNA3. The cells were cultured in
the absence (black columns) or presence (white columns) of
100 ng/mL pertussis toxin (ptx). The level of binding to
vector control membranes is indicated by the stapled line.
The results represent mean  SEM of raw data from three
independent experiments performed in triplicates. *P < 0.05
by Student’s t-test. (E) [
35S]GTPgS binding to membranes iso-
lated from 1321N1 cells transiently transfected with mGPR17
or pcDNA3; performed and presented as in D. *P < 0.05 by
Student’s t-test. (F) Homologous competition assay for
[
3H]LTD4 binding to the membranes from HEK293 cells tran-
siently transfected with mGPR17 or pcDNA3; these were
similar to those used in D. The data represent mean  SEM of
raw data from four independent experiments performed in
duplicates.
Figure S3 LTC4 does not activate or bind to either of the
hGPR17 isoforms or mGPR17. (A) Response to LTC4 in
HEK293 cells transiently transfected with Gqi4myr, CREB-Luc
reporter plasmid and FLAG-tagged hGPR17-L, -S or pcDNA3
at 15 ng per well. The results represent mean  SEM of raw
data from three independent experiments performed in qua-
druples. (B) Activation of FLAG-tagged CysLT2 by LTC4; per-
formed and presented as in A. The EC50 value is indicated by
the stapled line. (C) Homologous competition assay for
[
3H]LTC4 binding to the membranes from HEK293 cells tran-
siently transfected with hGPR17-L, -S, CysLT2 or pcDNA3.
The data represent mean  SEM of raw data from three inde-
pendent experiments performed in duplicates. The IC50 value
for CysLT2 is indicated by the stapled line. (D) Response to
LTC4 in HEK293 cells transiently transfected with Gqi4myr,
CREB-Luc reporter plasmid and FLAG-tagged mGPR17 or
pcDNA3 at 15 ng per well. The results represent mean  SEM
of raw data from three independent experiments performed
in quadruples. (E) Homologous competition assay for
[
3H]LTC4 binding to the membranes from HEK293 cells tran-
siently transfected with mGPR17, CysLT2 or pcDNA3. The
data represent mean  SEM of raw data from three indepen-
dent experiments performed in duplicates. The IC50 value for
CysLT2 is indicated by the stapled line.
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